Funding

SiccaNova Therapeutics

Japan · Biotech

A biotechnology company developing an oral drug candidate for dry mouth and related gland-function disorders.

Visit siccanova.comFunding history

Amplifying the body's own receptor signal

SiccaNova's XF8302 is a positive allosteric modulator of the muscarinic M3 receptor. It is designed to amplify receptor activation by the body's acetylcholine, with dry mouth associated with Sjögren's syndrome as an initial development focus.

The Tsukuba company is preparing clinical development in that indication while advancing manufacturing, nonclinical studies and regulatory work. It is also exploring related applications, including dry eye.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A¥1.3BJIC Venture Growth Investments Co., Ltd. — ParticipantJoyo Capital Partners Co., Ltd. — ParticipantRed Capital Co., Ltd. — ParticipantShichiju Shichu Capital Co., Ltd. — ParticipantTohoku University Venture Partners Co., Ltd. — ParticipantWPower Fund I — Participant

Investors

JIC Venture Growth Investments Co., Ltd.Joined Series AJoyo Capital Partners Co., Ltd.Joined Series ARed Capital Co., Ltd.Joined Series AShichiju Shichu Capital Co., Ltd.Joined Series ATohoku University Venture Partners Co., Ltd.Joined Series AWPower Fund IJoined Series A

Coverage

Sep 3, 2026SiccaNova Therapeutics · Series A

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesprtimes.jp ↗